Corbenic Partners LLC Editas Medicine, Inc. Transaction History
Corbenic Partners LLC
- $380 Million
- Q2 2022
A detailed history of Corbenic Partners LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Corbenic Partners LLC holds 141 shares of EDIT stock, worth $197. This represents 0.0% of its overall portfolio holdings.
Number of Shares
141
Previous 141
-0.0%
Holding current value
$197
Previous $3,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding EDIT
# of Institutions
218Shares Held
46.4MCall Options Held
436KPut Options Held
324K-
Black Rock Inc. New York, NY7.78MShares$10.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.47MShares$10.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.66MShares$3.72 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL2.6MShares$3.64 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.94MShares$2.72 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $96.2M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...